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0264-410X/ 2020 Elsevier Ltd. All rights reserved.The world is experiencing a major pandemic with a high mor-
tality. One can hope that the outbreak will end spontaneously after
most people are infected, but the SARS-2 coronavirus may become
endemic and continue to cause cycles of respiratory disease and
fatal pneumonias. A vaccine that is shown to give immunity is
the only practical way of preventing the virus from continuing to
cause widespread serious and often fatal illness and economic
destruction. Developing one and distributing an efficacious vaccine
as quickly as possible is a moral imperative for the world.
Vaccine development is usually a long process, requiring years
to move from animal tests to a series of human trials to regulatory
licensure. Safety of a vaccine must be confirmed by extensive ani-
mal work, followed by the inoculation of dozens of humans, then
escalating to thousands. The demonstration of efficacy normally
depends on collecting and comparing cases in thousands of indi-
viduals who randomly receive vaccine or placebo [1]. That process
normally takes months to years, during which SARS-2 will infect
and possibly kill millions. Acceleration of that standard process is
necessary.
However, the recognition that new viruses continue to emerge
and cause human disease, often leading to epidemic diseases has
stimulated vaccine developers to rethink the usual path of devel-
opment. For example, this path was shortened in the case of the
Ebola outbreak inWest Africa by comparing disease in two regions,
in one of which vaccine had been distributed. That process allowed
demonstration of efficacy in 10 months from the first clinical trials
[2]. Others, including ourselves, are proposing to obtain prelimi-
nary safety and efficacy data in human volunteers to accelerate
use of an effective vaccine.
Considering the rapid spread of the SARS-2 coronavirus and its
mortality rate, which exceeds that of the 1918–19 influenza epi-
demic, a vaccine is urgently needed [3]. Multiple candidates have
been proposed and many are in clinical trials, but the question
remains as to whether emergency use of a SARS-2 vaccine should
await collection of controlled data from large populations that
are experiencing epidemic SARS-2 disease or whether to expedite
vaccination by moving quickly through animal studies and doing
human challenge studies in volunteers [4]. Human volunteer chal-
lenge studies have been done previously with several agents, yield-
ing important information [5,6]. Of course, such studies put
volunteers at risk of disease and death and deaths have occurred
in drug studies. The ethics of such trials, as well as their acceptabil-
ity to regulators as a step towards emergency use of a candidate
vaccine are foremost and require immediate discussion.
In the case of SARS-2 infection a challenge study could take
advantage of the lower rate of death in 18–29 year olds. In thatage group in China, the death rate was 0.03%, not negligible but rel-
atively uncommon [7]. Nevertheless, a challenge study would
require controls who receive no vaccine and who might become
ill. Possible rescue treatments are being tested, such as remdesiver,
convalescent serum, and other modalities which could be used in
case of a severe disease after challenge, or administered as soon
as virus positivity is confirmed [8]. Morally those volunteering
would need to be free from coercion of any sort and their consent
revalidated by research ethic committees. Volunteers might
include those who are at high risk of exposure to the virus in the
ordinary course of their work or living arrangements. Still, despite
the danger we believe it is ethical to ask now for volunteers who
would be informed about the known and unknown risks. They
would be carefully screened and selected for their understanding
of the risks for death and disability. Meanwhile, it will take some
weeks to prepare a pool of challenge virus and to verify treatment
modalities such as antivirals and antibodies. The availability of top
tier researchers at high level medical facilities would be essential
to the acceptability of these challenge studies.
The first step in a SARS-2 challenge study would be to adminis-
ter virus to volunteers who have serologic evidence of prior infec-
tion. That step would determine whether immune responses are
protective and give some information about which immune
responses are important. Subsequent studies would include vacci-
nees and seronegative controls. Challenges would be done first
with low doses to determine the minimal infectious dose. Analysis
of immune responses in vaccinees who resist infection would give
important information about correlates of protection, allowing
judgments to be made about the probable efficacy of vaccines
developed subsequently.
The production of a challenge virus under Good Manufacturing
Practices conditions will take time and challenge studies should
not be done before there is agreement among regulators and ethi-
cists that the results of those studies are acceptable means to con-
firm efficacy. If vaccine development moves more rapidly perhaps
challenge studies will not be necessary. However, regulators and
ethicists should take into account the time required for an efficacy
study and the likelihood that control groups in typical phase 3 effi-
cacy studies of SARS-2 vaccines will suffer more deaths than in
carefully done human challenges, to say nothing about simultane-
ous deaths in people not in the studies exposed to circulating virus.
Moreover, it would be possible for regulators to allow emergency
use based on the results of challenge studies, and to continue col-
lecting data in the usual fashion for licensure at a later date. Delib-
erately causing disease in humans is normally abhorrent, but
asking volunteers to take risks without pressure or coercion is
3988 Editorial / Vaccine 38 (2020) 3987–3988not exploitation but benefitting from altruism. We are aware of
multiple offers from people willing to volunteer for the challenge
studies. As Shakespeare put it, ‘‘Desperate diseases by desperate
measures are relieved.”
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